Xeris Biopharma Holdings Inc (referred to as Xeris) announced today that the company will firmly uphold and defend its intellectual property rights related to the innovative drug Recorlev.

The company emphasized that it will take all necessary legal measures to address any actions that may infringe upon its patent protection. As a biopharmaceutical company focused on innovative therapies for endocrine diseases, Xeris Pharmaceuticals has established core patent barriers for Recorlev through continuous investment in research and development. The company stated that intellectual property is an important safeguard for its innovative achievements, and in the future, it will ensure the exclusive market rights of its products through legal means.